30 September 2020
London, 30 September 2020 – Tiziana Life Sciences plc (“Tiziana”, AIM: TILS, NASDAQ: TLSA), a biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases today announces its interim results for the six months ended 30 June 2020.Read more
25 September 2020
Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money ReportRead more
21 September 2020
London, New York, 21 September 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and...Read more
Our mission is to bring breakthrough therapies to patients with the aim of treating Crohn's Disease, COVID-19, Pro-MS and HCC and optimizing health outcomes.Learn more
With two Phase II and two pre-clinical candidates our development portfolio is supported by extensive IP and a strong pipeline of in-licensed clinical and pre-clinical assets.
Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of Crohn’ s Disease and a neurodegenerative indication.Learn more about Foralumab
Milciclib is the Company’s Phase 2 clinical candidate for the treatment of multiple cancer indications such as hepatocellular carcinoma, thymic cancer and thymoma.Learn more about Milciclib
With several candidates being prepared for clinic, our development portfolio is supported by extensive IP and a strong pipeline of in-licenced clinical and pre-clinical assets.
We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6 as a potential treatment for certain patients infected with COVID-19.Learn more about Anti IL-6R
StemPrintER is a multi-gene signature assay intended for use as a prognostic in patients with estrogen-receptor positive ER+/HER2 negative breast cancers.Learn more about StemPrintER™
Tiziana is currently conducting clinical development programs for Foralumab and Milciclib
Tiziana reported postive clinical data in a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston. Phase 2 for both orally administered Foralumab for the treatment of Crohn's disease and nasally administered Foralumab for the treatment of Pro-MS is anticipated to be complete in Q2 2021.See more Foralumab clinical trials
We reported positive Phase 2a clinical data exhibiting positive clinical activity with Milciclib Monotherapy in advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma. We intend to initiate Phase 2b with Milciclib in Combination with a TKI in Q2 2021See more Milciclib clinical trials